ARTICLE | Tools & Techniques

UTHR thinks expansively in hypertension

April 3, 2000 7:00 AM UTC

The release of statistically significant preliminary Phase III data for United Therapeutics Inc.'s Uniprost (UT-15) positions the company to compete in the primary pulmonary hypertension market, where the only existing treatment is Glaxo Wellcome's Flolan epoprostenol intravenous prostacyclin.

Uniprost is a subcutaneously administered prostacyclin analog that acts as a vasodilator and inhibitor of platelet aggregation. In a double-blind study in 470 patients, patients on Uniprost showed improvement in their ability to exercise, the primary end point (p<0.02). In addition, patients receiving Uniprost showed improvement in cardiopulmonary hemodynamics (p<0.001)...